WO1991009118A3 - Proteines fibrinolytiques et antithrombotiques activables - Google Patents
Proteines fibrinolytiques et antithrombotiques activables Download PDFInfo
- Publication number
- WO1991009118A3 WO1991009118A3 PCT/GB1990/001912 GB9001912W WO9109118A3 WO 1991009118 A3 WO1991009118 A3 WO 1991009118A3 GB 9001912 W GB9001912 W GB 9001912W WO 9109118 A3 WO9109118 A3 WO 9109118A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pct
- fibrinolytic
- activatable
- clot formation
- date jun
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
- C07K14/3153—Streptokinase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/108—Plasmid DNA episomal vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/32—Vector systems having a special element relevant for transcription being an silencer not forming part of the promoter region
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/55—Vector systems having a special element relevant for transcription from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/70—Vector systems having a special element relevant for transcription from fungi
- C12N2830/702—Vector systems having a special element relevant for transcription from fungi yeast
- C12N2830/704—S. cerevisiae
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
- C12N2840/107—Vectors comprising a special translation-regulating system regulates levels of translation inhibiting translational read-through
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69031127T DE69031127T2 (de) | 1989-12-07 | 1990-12-07 | Aktivierbare fibrinolytische und antithrombotische proteine |
KR1019920701348A KR100188302B1 (ko) | 1989-12-07 | 1990-12-07 | 활성화피브린용해성과항-혈전성단백질 |
EP91900851A EP0502968B1 (fr) | 1989-12-07 | 1990-12-07 | Proteines fibrinolytiques et antithrombotiques activables |
US07/854,603 US5637492A (en) | 1989-12-07 | 1990-12-07 | Activatable fibrinolytic and anti-thrombotic proteins |
NO922238A NO305562B1 (no) | 1989-12-07 | 1992-06-05 | FremgangsmÕte for fremstilling av en plasminogenanalog, syntetisk eller rekombinant nukleinsyre som koder for den, vektorer som omfatter en slik nukleinsyresekvens, samt celler eller cellelinjer som kan fremstille plasminogenanalogen |
FI922610A FI105202B (fi) | 1989-12-07 | 1992-06-05 | Menetelmä aktivoitavien fibrinolyyttisten ja veren hyytymistä estävien plasminogeenianalogien valmistamiseksi |
US08/147,000 US5688664A (en) | 1990-12-07 | 1993-10-29 | Thrombin activatable plasminogen analogues |
GR970402633T GR3024990T3 (en) | 1989-12-07 | 1997-10-09 | Activatable fibrinolytic and anti-thrombotic proteins |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB898927722A GB8927722D0 (en) | 1989-12-07 | 1989-12-07 | Proteins and nucleic acids |
GB8927722.2 | 1989-12-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1991009118A2 WO1991009118A2 (fr) | 1991-06-27 |
WO1991009118A3 true WO1991009118A3 (fr) | 1991-10-31 |
Family
ID=10667597
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1990/001911 WO1991009125A1 (fr) | 1989-12-07 | 1990-12-07 | Proteines et acides nucleiques |
PCT/GB1990/001912 WO1991009118A2 (fr) | 1989-12-07 | 1990-12-07 | Proteines fibrinolytiques et antithrombotiques activables |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1990/001911 WO1991009125A1 (fr) | 1989-12-07 | 1990-12-07 | Proteines et acides nucleiques |
Country Status (21)
Country | Link |
---|---|
US (2) | US5434073A (fr) |
EP (2) | EP0502968B1 (fr) |
JP (2) | JP2851423B2 (fr) |
KR (2) | KR920703818A (fr) |
AT (1) | ATE155812T1 (fr) |
AU (3) | AU644399B2 (fr) |
CA (2) | CA2069085C (fr) |
DE (1) | DE69031127T2 (fr) |
DK (1) | DK0502968T3 (fr) |
ES (1) | ES2106073T3 (fr) |
FI (2) | FI922609A (fr) |
GB (1) | GB8927722D0 (fr) |
GR (1) | GR3024990T3 (fr) |
HU (1) | HU211628A9 (fr) |
IE (2) | IE81046B1 (fr) |
IL (2) | IL96601A (fr) |
NO (2) | NO305562B1 (fr) |
NZ (2) | NZ236330A (fr) |
PT (2) | PT96103B (fr) |
WO (2) | WO1991009125A1 (fr) |
ZA (2) | ZA909854B (fr) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU22277A1 (es) * | 1990-05-23 | 1995-01-31 | Cigb | Procedimiento para el aislamiento y expresion de un gen codificante para estreptoquinasa,secuencia nucleotidica obtenida,adn recombinantes y microorganismos transformados |
GB9222758D0 (en) * | 1992-10-29 | 1992-12-09 | British Bio Technology | Proteins and nucleic acids |
GB9216558D0 (en) * | 1992-08-04 | 1992-09-16 | British Bio Technology | Modified proteases |
GB2286190B (en) * | 1992-10-29 | 1996-05-01 | British Biotech Pharm | Thrombin activatable plasminogen derivatives |
DE4323754C1 (de) * | 1993-07-15 | 1994-12-01 | Gruenenthal Gmbh | Bifunktionelle Urokinasevarianten mit verbesserten fibrinolytischen Eigenschaften und thrombinhemmender Wirkung |
JPH08502661A (ja) * | 1993-08-04 | 1996-03-26 | チバ−ガイギー アクチェンゲゼルシャフト | 高分子量デスルファトヒルジン |
ES2080657B1 (es) * | 1993-09-27 | 1996-11-01 | Britisch Bio Technology Limite | Proteasas modificadas. |
US5837682A (en) | 1996-03-08 | 1998-11-17 | The Children's Medical Center Corporation | Angiostatin fragments and method of use |
CN1309833C (zh) * | 1994-04-26 | 2007-04-11 | 儿童医学中心公司 | 血管生成抑制素及其在制备药物中的用途 |
US5945403A (en) | 1997-05-30 | 1999-08-31 | The Children's Medical Center Corporation | Angiostatin fragments and method of use |
GB9412131D0 (en) * | 1994-06-17 | 1994-08-10 | British Bio Technology | Thrombolytic composition |
DE4440892A1 (de) * | 1994-11-17 | 1996-05-23 | Gruenenthal Gmbh | Proteine mit fibrinolytischen und gerinnungshemmenden Eigenschaften |
DE4442665A1 (de) * | 1994-11-30 | 1996-06-05 | Gruenenthal Gmbh | Chimäre Proteine mit fibrinolytischen und thrombinhemmenden Eigenschaften |
US5854049A (en) * | 1995-06-09 | 1998-12-29 | President And Fellows Of Harvard College | Plasmin-resistant streptokinase |
US5736364A (en) * | 1995-12-04 | 1998-04-07 | Genentech, Inc. | Factor viia inhibitors |
US6461640B1 (en) | 1995-12-08 | 2002-10-08 | Board Of Regents, The University Of Texas System | Local delivery of fibrinolysis enhancing agents |
KR20000029755A (ko) * | 1996-08-02 | 2000-05-25 | 로셰 디아그노스틱스 게엠베하 | 트롬빈에의해활성화될수있는플라스미노겐활성화제 |
DE69833755T2 (de) * | 1997-05-21 | 2006-12-28 | Biovation Ltd. | Verfahren zur herstellung von nicht-immunogenen proteinen |
ATE203567T1 (de) * | 1998-03-19 | 2001-08-15 | Instrumentation Lab Spa | Verbesserte in vitro verfahren, testkits und reagenzien zum screening von blutgerinnungsfehlern |
AU5571799A (en) | 1998-08-20 | 2000-03-14 | University Of Vermont And State Agricultural College, The | Angiogenesis inhibitors and uses thereof |
IN190822B (fr) * | 1998-12-24 | 2003-08-23 | Council Scient Ind Res | |
WO2001036351A2 (fr) | 1999-11-19 | 2001-05-25 | Corvas International, Inc. | Antagonistes de l'inhibiteur des activateurs du plasminogène |
US6423826B1 (en) * | 2000-06-30 | 2002-07-23 | Regents Of The University Of Minnesota | High molecular weight derivatives of vitamin K-dependent polypeptides |
US7160540B2 (en) | 2000-06-30 | 2007-01-09 | Regents Of The University Of Minnesota | Methods for detecting activity of clottings factors |
US20030211094A1 (en) | 2001-06-26 | 2003-11-13 | Nelsestuen Gary L. | High molecular weight derivatives of vitamin k-dependent polypeptides |
AU8591901A (en) * | 2000-09-05 | 2002-03-22 | Karolinska Innovations Ab | Materials and methods relating to endothelial cell growth inhibitors |
DE10108212A1 (de) * | 2001-02-20 | 2002-08-22 | Aventis Pharma Gmbh | Fusionsprotein zur Sekretion von Wertprotein in bakterielle Überstände |
DE10108100A1 (de) * | 2001-02-20 | 2002-08-29 | Aventis Pharma Gmbh | Verwendung supersekretierbarer Peptide in Verfahren zu deren Herstellung und paralleler Verbesserung der Exportate eines oder mehrerer anderer Polypeptide von Interesse |
US7202059B2 (en) | 2001-02-20 | 2007-04-10 | Sanofi-Aventis Deutschland Gmbh | Fusion proteins capable of being secreted into a fermentation medium |
DE10108211A1 (de) * | 2001-02-20 | 2002-08-22 | Aventis Pharma Gmbh | Verwendung von Fusionsproteinen, deren N-terminaler Anteil aus einem Hirudinderivat besteht, zur Herstellung rekombinanter Proteine über Sekretion durch Hefen |
US7638618B2 (en) * | 2001-02-20 | 2009-12-29 | Sanofi-Aventis Deutschland Gmbh | Nucleic acids encoding a hirudin and pro-insulin as superscretable peptides and for parallel improvement of the exported forms of one or more polypeptides of interest |
FR2831170B1 (fr) * | 2001-10-19 | 2004-03-19 | Inst Nat Sante Rech Med | Proteines c modifiees activables directement par la thrombine |
EP1572908A4 (fr) * | 2002-02-14 | 2008-10-22 | William J Rutter | Molecules chimeriques permettant d'administrer un clivage a un hote traite |
CN1480466A (zh) * | 2002-09-03 | 2004-03-10 | �й������ž�����ҽѧ��ѧԺ����ҽ | 一类溶栓抗凝双功能融合蛋白及应用 |
US7985401B2 (en) | 2003-10-31 | 2011-07-26 | The Regents Of The University Of California | Peptides whose uptake by cells is controllable |
US9695251B2 (en) | 2003-10-31 | 2017-07-04 | The Regents Of The University Of California | Activatable cell penetrating peptides with quenched fluorophores |
JP5800458B2 (ja) | 2006-06-14 | 2015-10-28 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 血液凝固因子を有するタンパク質分解によって切断可能な融合タンパク質 |
EP1867660A1 (fr) | 2006-06-14 | 2007-12-19 | CSL Behring GmbH | Protéine de fusion qui peut être clivée protéolyticalement et qui contient un facteur de la coagulation sanguine |
US7939632B2 (en) | 2006-06-14 | 2011-05-10 | Csl Behring Gmbh | Proteolytically cleavable fusion proteins with high molar specific activity |
GB2455262A (en) * | 2006-09-29 | 2009-06-10 | Proteomtech Inc | Methods for production of recombinant plasminogen and plasmin polypeptides |
CN1970574B (zh) * | 2006-12-08 | 2010-08-25 | 中国药科大学 | 溶栓和抗凝双重功效融合蛋白、制备方法及其应用 |
EP2097096B1 (fr) | 2006-12-22 | 2017-05-31 | CSL Behring GmbH | Facteurs de coagulation modifiés avec une demi-vie in vivo prolongée |
US8501449B2 (en) | 2007-12-04 | 2013-08-06 | Proteon Therapeutics, Inc. | Recombinant elastase proteins and methods of manufacturing and use thereof |
US20110262466A1 (en) * | 2008-10-16 | 2011-10-27 | The Trustees Of The University Of Pennsylvania | Compositions containing thrombomodulin domains and uses thereof |
EP2396347B1 (fr) | 2009-02-11 | 2017-04-12 | Albumedix A/S | Variants et conjugés de l'albumine |
CA2770980A1 (fr) * | 2009-07-15 | 2011-01-20 | Roger Y. Tsien | Peptides dont l'absorption par les cellules peut etre regulee |
BR112012009450A2 (pt) | 2009-10-30 | 2017-05-23 | Novozymes Biopharma Dk As | variantes de albumina |
US9150844B2 (en) * | 2010-08-05 | 2015-10-06 | Neeraj Maheshwari | Protein fusion constructs possessing thrombolytic and anticoagulant properties |
WO2013019681A2 (fr) | 2011-07-29 | 2013-02-07 | Avelas Biosciences, Inc. | Molécules de délivrance sélective et procédés d'utilisation |
AU2012296884B2 (en) | 2011-08-12 | 2015-02-05 | Thrombogenics N.V. | Plasminogen and plasmin variants |
WO2013075066A2 (fr) | 2011-11-18 | 2013-05-23 | Eleven Biotherapeutics, Inc. | Protéines ayant une demi-vie et d'autres propriétés améliorées |
WO2013135896A1 (fr) | 2012-03-16 | 2013-09-19 | Novozymes Biopharma Dk A/S | Variants d'albumine |
WO2014072481A1 (fr) | 2012-11-08 | 2014-05-15 | Novozymes Biopharma Dk A/S | Variants d'albumine |
WO2014120837A2 (fr) | 2013-01-29 | 2014-08-07 | The Regents Of The University Of California | Peptide à pénétration cellulaire activable pré-ciblé comportant un promédicament à libération intracellulaire |
KR102278630B1 (ko) | 2013-01-30 | 2021-07-16 | 아벨라스 바이오사이언시즈 인코포레이티드 | 선택적 전달 분자 및 사용 방법 |
WO2014125082A1 (fr) | 2013-02-16 | 2014-08-21 | Novozymes Biopharma Dk A/S | Modèle pharmacocinétique animal |
US10385380B2 (en) | 2014-10-02 | 2019-08-20 | The Regents Of The University Of California | Personalized protease assay to measure protease activity in neoplasms |
US10596259B2 (en) | 2015-05-20 | 2020-03-24 | The Regents Of The University Of California | Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof |
BR112018003179A2 (pt) | 2015-08-20 | 2018-09-25 | Albumedix As | conjugados e variantes de albumina |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0211299A2 (fr) * | 1985-07-27 | 1987-02-25 | Hoechst Aktiengesellschaft | Protéines fusionnées, procédé de production et utilisation de celles-ci |
EP0227938A2 (fr) * | 1985-11-27 | 1987-07-08 | Hoechst Aktiengesellschaft | Protéines de fusion eucaryotes, leur préparation et leur utilisation ainsi que le moyen pour la mise en oeuvre du procédé |
EP0292009A1 (fr) * | 1987-05-22 | 1988-11-23 | Zymogenetics, Inc. | Protéines fibrinolytiques |
EP0297882A2 (fr) * | 1987-07-01 | 1989-01-04 | Beecham Group Plc | Activateurs de plasminogène hybrides |
WO1989001036A1 (fr) * | 1987-07-23 | 1989-02-09 | Celltech Limited | Vecteurs d'expression a base d'adn recombinant |
EP0304013A2 (fr) * | 1987-08-15 | 1989-02-22 | Asahi Kasei Kogyo Kabushiki Kaisha | Protéine précurseur de l'amyloide sénile et un anticorps spécifique |
EP0319944A2 (fr) * | 1987-12-08 | 1989-06-14 | Zymogenetics, Inc. | Co-expression dans des cellules eucaryotes |
EP0323149A2 (fr) * | 1987-12-28 | 1989-07-05 | Eli Lilly And Company | Vecteurs et composés pour l'expression de formes zymogéniques de protéine C |
WO1989006239A1 (fr) * | 1987-12-28 | 1989-07-13 | Teijin Limited | Polypeptides inhibiteurs d'elastase et procede de production de ces polypeptides par recombinaison genetique |
EP0330700A1 (fr) * | 1987-08-19 | 1989-09-06 | Sagami Chemical Research Center | Polypeptide ressemblant à la prourokinase humaine |
EP0338841A1 (fr) * | 1988-04-18 | 1989-10-25 | Celltech Limited | Procédés d'ADN recombinant, vecteurs et cellules hôtes |
WO1990010081A1 (fr) * | 1989-02-17 | 1990-09-07 | Codon | Analogues solubles de la thrombomoduline |
WO1990013640A1 (fr) * | 1989-05-01 | 1990-11-15 | The University Of Notre Dame Du Lac | Procedes et substances d'expression du plasminogene humain dans un systeme de cellules eukaryotiques |
WO1991008297A1 (fr) * | 1989-12-01 | 1991-06-13 | Genentech, Inc. | Procedes et matieres d'expression de variante de plasminogene humain |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1897087A (en) * | 1927-12-14 | 1933-02-14 | Tamarin Bernard Jacques | Vacuum cleaner cord control device |
US3608333A (en) * | 1968-06-20 | 1971-09-28 | Bison Mfg Co Inc | Vacuum cleaner and power unit |
US4880776A (en) * | 1983-12-24 | 1989-11-14 | Beecham Group P.L.C. | Plasmin A-chain urokinase B-chain hybrid protein |
GB8334498D0 (en) * | 1983-12-24 | 1984-02-01 | Beecham Group Plc | Compounds |
DE3410437A1 (de) * | 1984-03-22 | 1985-09-26 | Bayer Ag, 5090 Leverkusen | Verfahren zur herstellung von proteinen |
GB8412517D0 (en) * | 1984-05-16 | 1984-06-20 | Nagai K | Recombinant fusion proteins |
US5087564A (en) * | 1985-06-20 | 1992-02-11 | Monsanto Company | Release of recombinant peptides from polypeptides using V8 endopeptidase |
DE3523701A1 (de) * | 1985-07-03 | 1987-01-08 | Bayer Ag | Verfahren zur herstellung von proteinen und polypeptiden |
US5200340A (en) * | 1987-05-22 | 1993-04-06 | Zymogenetics, Inc. | Thrombin-activated tissue plasminogen activators |
JP2799316B2 (ja) * | 1987-06-12 | 1998-09-17 | ヘキスト・マリオン・ルセル株式会社 | 雑種ヒトプロテインcおよびその遺伝子工学的製法 |
DE3804600A1 (de) * | 1988-02-13 | 1989-08-24 | Basf Ag | Mischung aus einer thrombolytisch wirkenden und einer antithrombotischen substanz |
GB8822147D0 (en) * | 1988-09-21 | 1988-10-26 | Ciba Geigy Ag | Pharmaceutically active combination |
US5164304A (en) * | 1989-05-04 | 1992-11-17 | Sri International | Method and vectors for stabilizing hirudin and human laminin b1 expression |
EP0561034B1 (fr) * | 1991-08-26 | 1999-06-09 | IMMUNO Aktiengesellschaft | Clonage moléculaire direct d'un génome modifié d'un virus chordopox |
-
1989
- 1989-12-07 GB GB898927722A patent/GB8927722D0/en active Pending
-
1990
- 1990-12-04 NZ NZ236330A patent/NZ236330A/en unknown
- 1990-12-06 PT PT96103A patent/PT96103B/pt not_active IP Right Cessation
- 1990-12-06 PT PT96104A patent/PT96104A/pt unknown
- 1990-12-07 KR KR1019920701305A patent/KR920703818A/ko not_active Application Discontinuation
- 1990-12-07 JP JP3501315A patent/JP2851423B2/ja not_active Expired - Fee Related
- 1990-12-07 AT AT91900851T patent/ATE155812T1/de not_active IP Right Cessation
- 1990-12-07 AU AU69540/91A patent/AU644399B2/en not_active Ceased
- 1990-12-07 ES ES91900851T patent/ES2106073T3/es not_active Expired - Lifetime
- 1990-12-07 EP EP91900851A patent/EP0502968B1/fr not_active Expired - Lifetime
- 1990-12-07 NZ NZ236401A patent/NZ236401A/en unknown
- 1990-12-07 ZA ZA909854A patent/ZA909854B/xx unknown
- 1990-12-07 KR KR1019920701348A patent/KR100188302B1/ko not_active IP Right Cessation
- 1990-12-07 IL IL9660190A patent/IL96601A/en not_active IP Right Cessation
- 1990-12-07 US US07/854,596 patent/US5434073A/en not_active Expired - Fee Related
- 1990-12-07 WO PCT/GB1990/001911 patent/WO1991009125A1/fr not_active Application Discontinuation
- 1990-12-07 IE IE441790A patent/IE81046B1/en not_active IP Right Cessation
- 1990-12-07 IE IE441690A patent/IE904416A1/en unknown
- 1990-12-07 AU AU69656/91A patent/AU643247B2/en not_active Ceased
- 1990-12-07 DE DE69031127T patent/DE69031127T2/de not_active Expired - Fee Related
- 1990-12-07 EP EP91900869A patent/EP0504241A1/fr not_active Withdrawn
- 1990-12-07 IL IL96602A patent/IL96602A0/xx unknown
- 1990-12-07 ZA ZA909853A patent/ZA909853B/xx unknown
- 1990-12-07 US US07/854,603 patent/US5637492A/en not_active Expired - Lifetime
- 1990-12-07 CA CA002069085A patent/CA2069085C/fr not_active Expired - Lifetime
- 1990-12-07 WO PCT/GB1990/001912 patent/WO1991009118A2/fr active IP Right Grant
- 1990-12-07 JP JP3501314A patent/JPH05502374A/ja not_active Expired - Lifetime
- 1990-12-07 CA CA002069105A patent/CA2069105A1/fr not_active Abandoned
- 1990-12-07 DK DK91900851.6T patent/DK0502968T3/da active
-
1992
- 1992-06-05 NO NO922238A patent/NO305562B1/no not_active IP Right Cessation
- 1992-06-05 FI FI922609A patent/FI922609A/fi unknown
- 1992-06-05 FI FI922610A patent/FI105202B/fi active
- 1992-06-05 NO NO92922237A patent/NO922237L/no unknown
-
1993
- 1993-08-30 AU AU44976/93A patent/AU4497693A/en not_active Abandoned
-
1995
- 1995-06-22 HU HU95P/P00384P patent/HU211628A9/hu unknown
-
1997
- 1997-10-09 GR GR970402633T patent/GR3024990T3/el unknown
Patent Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0211299A2 (fr) * | 1985-07-27 | 1987-02-25 | Hoechst Aktiengesellschaft | Protéines fusionnées, procédé de production et utilisation de celles-ci |
EP0227938A2 (fr) * | 1985-11-27 | 1987-07-08 | Hoechst Aktiengesellschaft | Protéines de fusion eucaryotes, leur préparation et leur utilisation ainsi que le moyen pour la mise en oeuvre du procédé |
EP0292009A1 (fr) * | 1987-05-22 | 1988-11-23 | Zymogenetics, Inc. | Protéines fibrinolytiques |
EP0297882A2 (fr) * | 1987-07-01 | 1989-01-04 | Beecham Group Plc | Activateurs de plasminogène hybrides |
WO1989001036A1 (fr) * | 1987-07-23 | 1989-02-09 | Celltech Limited | Vecteurs d'expression a base d'adn recombinant |
EP0304013A2 (fr) * | 1987-08-15 | 1989-02-22 | Asahi Kasei Kogyo Kabushiki Kaisha | Protéine précurseur de l'amyloide sénile et un anticorps spécifique |
EP0330700A1 (fr) * | 1987-08-19 | 1989-09-06 | Sagami Chemical Research Center | Polypeptide ressemblant à la prourokinase humaine |
EP0319944A2 (fr) * | 1987-12-08 | 1989-06-14 | Zymogenetics, Inc. | Co-expression dans des cellules eucaryotes |
EP0323149A2 (fr) * | 1987-12-28 | 1989-07-05 | Eli Lilly And Company | Vecteurs et composés pour l'expression de formes zymogéniques de protéine C |
WO1989006239A1 (fr) * | 1987-12-28 | 1989-07-13 | Teijin Limited | Polypeptides inhibiteurs d'elastase et procede de production de ces polypeptides par recombinaison genetique |
EP0338841A1 (fr) * | 1988-04-18 | 1989-10-25 | Celltech Limited | Procédés d'ADN recombinant, vecteurs et cellules hôtes |
WO1990010081A1 (fr) * | 1989-02-17 | 1990-09-07 | Codon | Analogues solubles de la thrombomoduline |
WO1990013640A1 (fr) * | 1989-05-01 | 1990-11-15 | The University Of Notre Dame Du Lac | Procedes et substances d'expression du plasminogene humain dans un systeme de cellules eukaryotiques |
WO1991008297A1 (fr) * | 1989-12-01 | 1991-06-13 | Genentech, Inc. | Procedes et matieres d'expression de variante de plasminogene humain |
Non-Patent Citations (4)
Title |
---|
Archives of Biochemistry and Biophysics, vol. 271, no. 2, June 1989, Academic Press, Inc., J. Whitefllet-Smith et al.: "Expression of human plasminogen cDNA in a baculovirus vector-infected insect cell system", pages 390-399 * |
Biochemistry, vol. 29, 1990, American Chemical Society, D.J. Davidson et al.: "plasminogen activator activities of equimolar complexes of streptokinase with variant recombinant plasminogens", pages 3585-3590 * |
Chemical Abstracts, vol. 103, 1985, (Columbus, Ohio, US), J.Y. Chang: "Thrombin specificity. Requirement for apolar amino acids adjacent to the thrombin cleavage site of polypeptiede substrate", see page 412 * |
Proc. Natl. Acad. Sci. USA, vol. 79, October 1982, T. Miyata et al.: "Plasminogen Tochigi: inactive plasmin resulting from replacement of alanine-600 by threonine in the active site", pages 6132-6136 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU4497693A (en) | Activatable fibrinolytic and anti-thrombotic proteins | |
Stocker et al. | Thrombin-like snake venom proteinases | |
Seegers | Antithrombin III. Theory and Clinical Applications: HP Smith Memorial Lecture | |
ES2018729A6 (es) | Un metodo para preparar una variante de activador de plasmogeno de tejido. | |
EP0401508A3 (fr) | Inhibiteurs de protéinase, leur procédé de préparation ainsi que compositions pharmaceutiques les contenant | |
Gertler et al. | Prothrombotic and fibrinolytic function of normal and perturbed endothelium | |
Pâques et al. | Comparative study on the in vitro effectiveness of antithrombotic agents | |
Saba et al. | Effect of lysosomal cationic proteins from polymorphonuclear leukocytes upon the fibrinogen and fibrinolysis system | |
Daoud et al. | Mechanism of the anticoagulant, Cerastase F-4, isolated from Cerastes cerastes (Egyptian sand viper) venom | |
Pirkle et al. | Thrombin-like venom enzymes: structure and function | |
EP0218479A3 (en) | Reagent and process | |
Zhang et al. | Effects of Pallas' viper (Agkistrodon halys pallas) venom on blood coagulation and characterization of a prothrombin activator | |
FI932196A (fi) | Foerfarande foer bestaemning av fibrinogen | |
EP0326013A3 (fr) | Protéines dérivées de l'inhibiteur de l'alpha-2-plasmine humaine ou protéines similaires à celles-ci | |
Andersson | Purification and studies of components of the haemostatic system by affinity chromatography | |
Gould et al. | Design of antithrombotic agents: An introduction | |
KLÖCKING et al. | Recent Developments in Toxicology: Trends, Methods and Problems Arch. Toxicol., Suppl. 14, 157–159 (1991) Springer-Verlag 1991 | |
Loskutoff et al. | Activation of Hageman factor by cultured rabbit endothelial cells | |
Klöcking et al. | Effects of snake venoms on tissue-type plasminogen activator release | |
Stief et al. | Specificity of functional determination of urokinase in human plasma using selective oxidants | |
Cederholm-Williams | Molecular mechanism of fibrinolysis and its potential role in metastasis | |
Chen | Purification and characterization of M5, a hemorrhagic fibrinolytic protease from Crotalus molossus molossus (Northern blacktailed rattlesnake) venom |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA FI HU JP KR NO US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA FI HU JP KR NO US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2069085 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1991900851 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 922610 Country of ref document: FI |
|
WWP | Wipo information: published in national office |
Ref document number: 1991900851 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1991900851 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 922610 Country of ref document: FI |